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Background and Purpose. The Solitaire Flow Restoration was approved by the FDA in 2012 for mechanical thrombolysis of
proximal occlusion of intracranial arteries. To compare the Solitaire FR device and theMerci/Penumbra (previously FDA approved)
systems in terms of safety, clinical outcomes, and efficacy including radiographic brain parenchymal salvage. Methods. Thirty-
one consecutive patients treated with the Solitaire and 20 patients with comparable baseline characteristics treated with Merci or
Penumbra systems were included in the study. Primary outcome measures included recanalization rate and modified Rankin Scale
score at followup. Secondary outcomes included length of procedure, incidence of symptomatic intracranial hemorrhage, 90-day
mortality, and radiographic analysis of percentage area salvage. Results. Compared with the Merci/Penumbra group, the Solitaire
group showed a statistically significant improvement in favorable outcomes (mRS≤ 2) (69% versus 35%,𝑃 = 0.03) and symptomatic
ICH rate (0 versus 15%,𝑃 = 0.05) with a trend towards higher recanalization rates (93.5% versus 75%, 𝑃 = 0.096) and shorter length
of procedure (58.5min versus 70.8min, 𝑃 = 0.08). Radiographic comparison also showed a significantly larger area of salvage in
the Solitaire group (81.9% versus 71.9%, 𝑃 = 0.05). Conclusion. Our study suggests that the Solitaire system allows faster, safer, and
more efficient thrombectomy than Merci or Penumbra systems.
1. Introduction
Thegoal of acute ischemic stroke treatment is arterial recanal-
ization and restoration of brain parenchymal perfusion. Since
the Food and Drug Administration (FDA) approval of tissue
plasminogen activator (tPA) for treatment of acute ischemic
stroke in 1996, intravenous tPA (ivtPA) administrationwithin
a 3–4.5 hours window postsroke has been the mainstream of
stroke intervention [1].
However, ivtPA therapy has shortcomings including a
limited administration window and less than ideal reper-
fusion outcome especially in large vessel occlusions. In
fact, the recanalization rate with ivtPA is as low as 10%
in internal carotid artery (ICA) occlusions and less than
30% for proximal middle cerebral artery (MCA) occlusions
[2]. As such, intra-arterial thrombolysis within 6 hours and
mechanical thrombectomy within 8 hours from symptom
onset have been increasingly used to achieve faster and more
efficient recanalizations of large arterial occlusions [1].
In the past decade, several randomized controlled tri-
als for intra-arterial thrombolytic therapy and mechanical
thrombolysis have been conducted and shown promising
results.These trials led to the FDA approval of the first throm-
bectomy device, the Merci Retriever (Merci, Concentric
Medical,MountainView, CA) in 2004, and the second device,
the Penumbra (Penumbra, Alameda, CA), in 2008. Although
both devices are associated with relatively high rates of
successful recanalization, large clots in major intracranial
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Figure 1: Thrombolysis protocol for acute ischemic stroke.
arteries remain quite resistant and require a prolonged time
for recanalization [3]. The Solitaire Flow Restoration (FR)
(ev3/Covidien, Irvine, CA) is a self-expanding, fully retriev-
able stent that obtained FDAapproval inMarch 2012 based on
the results of the Solitaire with the Intention for Thrombec-
tomy (SWIFT) trial. This study found higher recanalization
rates (61% versus 24%) and better neurologic outcomes (58%
versus 33%) in the Solitaire FR device compared with the
Merci device [4].
We present the first study comparing the Solitaire FR
device and the Merci and/or Penumbra systems in terms
of efficacy, safety, clinical outcomes, and area of territory
at risk saved with revascularization by analyzing pre and
postintervention imaging studies. We also reviewed pub-
lished large scale mechanical thrombectomy trials for Merci,
Penumbra,Merci 2, Solitaire, andTREVOdevices to compare
our Solitaire FR results with these various current devices.
2. Patients and Methods
2.1. Eligibility. This is a single-center study of 31 patients
treated with mechanical thrombectomy with the Solitaire FR
device at the Jefferson Hospital for Neuroscience (JHN) in
between March 2012 and November 2012. After neurologi-
cal examination, suspected acute stroke patients are either
admitted from Thomas Jefferson University Hospital emer-
gency department, transferred from affiliated community
hospitals, or directly accepted by the attending physician on
stroke telemedicine call. Upon arrival to the JHN, patients are
directly brought to the interventional neuroradiology (INR)
suite for full history and physical exam by neurosurgical
residents, fellows, and attending physicians. Subsequently,
patients meeting clinical criteria for intervention with no
CT evidence of completed stroke or hemorrhage proceed
to immediate CT perfusion of head and CT angiogram of
head and neck to determine the extent of territory at risk
and to identify a major intracranial arterial occlusion. Based
on the clinical signs, National Institute of Health Stroke
Scale (NIHSS), and imaging findings the decision is made
whether to performmechanical thrombolysis or not. Figure 1
details our patient selection protocol for thrombolysis. Major
criteria for intervention include poor NIHSS ≥ 5, large
territorial mismatch between cerebral blood volume and
blood flow/mean transit time on CT perfusion scan, visible
main arterial thrombus on CT angiogram, and worsening
neurological performance since time of referral [5]. Our
institution uses CT perfusion guided recanalization selection
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because it has reported lower intracranial hemorrhage rate
and mortality rates compared with time guided selection [6].
Contraindications to interventions are improving neurolog-
ical status, low NIHSS, and multiple medical comorbidities
with poor functional baseline.
2.2. Procedures. Procedures are performed under general
anesthesia and neuromonitoring with both somatosensory
and motor evoke potentials. Access is obtained on the side
contralateral to the intraluminal thrombus. The femoral
artery is the first choice followed by the radial, brachial,
and carotid arteries. The specific system used to support
the Solitaire FR device may be variable depending on the
patients peripheral vascular anatomy, presence of concurrent
carotid pathology, clot location, and/or operator discretion.
The majority of cases presented in this series achieved suc-
cessful results with a 7F sheath and selective catheterization
using a 0.038 Guide wire (Terumo, Somerset, NJ) and 6F
Envoy guide catheter (Codman Neurovascular, Raynham,
MA). Superselective catheterization of the target vessel was
achieved with a 0.014 inch Synchro-2 microwire (Stryker;
Fremont, CA) and Prowler Select Plus microcatheter (Cordis
Neurovascular, Miami Lakes, FL).
Placement of the microcatheter distal to the thrombus is
confirmed by microinjection of 60% contrast under digital
subtraction angiography (DSA). The Solitaire FR device
is then brought into the field and advanced through the
microcatheter with biplane fluoroscopy to confirm its central
position over the thrombus.Themicrocatheter is then pulled
back to unsheathe the Solitaire FR device while maintaining
a constant position of the Solitaire delivery wire.The Solitaire
FRdevice is left completely unsheathed for 3–5minutes.Once
the appropriate time has elapsed, the proximal 1/4 of the
Solitaire stent is retrieved within the microcatheter and then
pulled out thru the guide catheter under continuous negative
aspiration with a 50mL syringe. Some operators prefer the 8F
Merci Balloon Guide Catheter (Concentric Medical) so that
it may be inflated before aspiration with the 50mL syringe
to aid in thrombus retrieval. The substitution of this guide
catheter necessitates placement of an 8F sheath for access.
Control angiograms are performed after Solitaire retrieval to
confirm revascularization.
2.3. Outcome Measure. On admission, NIHSS and ivtPA
administration status were checked; NIHSS was reassessed
24 hours after intervention and at time of discharge. Baseline
modified Rankin Score (mRS) was obtained from family
on admission and reassessed at ≥90 days during a follow-
up office visit. CT head was performed within 24 h after
intervention to diagnose hemorrhagic complications. MRI
brainwas also performed 24 h after intervention to document
the area of completed stroke.
Primary outcome measures included recanalization rate
and modified Rank in Scale score at followup. Secondary
outcomes included length of procedure, incidence of symp-
tomatic intracranial hemorrhage, 90-day mortality rate, and
radiographic analysis of percentage area salvage. Successful
recanalization was defined as a Thrombolysis In Myocardial
Ischemia (TIMI) reperfusion grade of 2 or 3 on immediate
postprocedural angiograms. The area of brain parenchymal
salvage was documented by volumetric analysis. Specifically,
the volume of completed stroke on MRI DWI sequence
was subtracted from the volume of the territory at risk
on initial CT perfusion. The volume of territory at risk
was determined on initial CT head perfusion by measur-
ing the mismatched area between mean transit time and
blood volume in the axial plane and multiplying the total
calculated area by the slice thickness of the corresponding
image. The volume of completed stroke was measured on
DWI signal abnormality from 24 hr postintervention MRI
axial plane multiplied by the respective slice thickness with
corresponding signal changes. The difference in the territory
at risk on CT head perfusion study and DWI sequence in
MRI brain is the area salvage. The percentage salvage is
calculated using area salvage divided by the initial territory at
risk. All calculations were carried out by a neuroradiologist
with no prior knowledge of postoperative outcomes. Figure 3
shows the typical imaging studies from a Solitaire patient.
Safety outcome was assessed by (1) symptomatic intracranial
hemorrhage after intervention, (2) device-induced damage
to vessels and further propagation of thrombus, and (3)
mortality rate at 90 days. Postprocedural groin hematoma
was not included in safety outcome as this is a complication
expected in any angiographic procedure; however, we did
collect this data as procedure related complications.
The results from the Solitaire group were compared with
those of the Merci/Penumbra group. Comparison group
consisted of 20 patients treated with Merci and/or Penumbra
system as first choice device from February 2010 to January
2011 at our institution. The characteristics of patients in the
Merci, Penumbra group were comparable with the Solitaire
group in terms of age, sex, medical comorbidities, andNIHSS
in order to eliminate confounding variables. The focus of
the comparison was not only the clinical outcomes but also
the radiographic outcome of percentage area salvage; thus,
patients with nondiagnostic CT perfusion study or with
contraindications to MRI study such as those with a cardiac
pacer were not included in the comparison group. After
adjusting the confounding variables and availability of CT
perfusion and MRI study, only twenty patients qualified to
be included in the comparison group among the 44 total
patients treated with Merci or penumbra system previously.
Merci/Penumbra patients are grouped together because there
were not enough patients treated in either group alone that
would comprise a large enough comparison group.
2.4. Statistical Analysis. Data are presented as mean and
range for continuous variables and as frequency for categor-
ical variables. Analysis was carried out using unpaired 𝑡-test,
Chi-square, and Fisher’s exact tests as appropriate. Univariate
analysis was used to test covariates predictive of the following
dependent outcomes: unfavorable outcome (mRS 3–6) and
TIMI-2 or 3. 𝑃 values of ≤0.05 were considered statistically
significant. Statistical analysis was carried out with Stata 10.0
(College Station, TX).
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Table 1: Solitaire patient characteristics and treatment result.
Patient Age Gender NIHSS onarrival
NIHSS at
discharge ivTPA
Location
of
thrombus
Time to
reperfusion
(hrs)
Procedure
time
(min)
Rescue treatment∗ No. ofpass TIMI
F/U
mRS
1 87 F 18 13 N R M2 17 42 N 1 3 4
2 64 M 12 2 N L M1 11 90 N 2 3 1
3 73 M 12 5 Y L M1 7 36 N 1 3 2
4 32 M 18 0 Y R M2 5 33 N 1 3 0
5 50 M 21 2 N R ICA 5 65 N 1 2 1
6 52 M 7 1 N Basilar 6 73 N 1 3 0
7 76 M 12 4 N RM1 10 44 N 2 3 2
8 77 M 13 0 Y R M1 6 65 N 2 2 0
9 62 M 9 5 N L M2 5 70 N 1 2 2
10 77 F 13 5 Y L ICA 10 80 Y (Penum/Plasty) 1 3 2
11 48 M 12 0 N R M2 6 20 N 1 3 0
12 82 M 9 4 Y L M1 5 26 N 1 3 4
13 69 M 9 9 N L vert 6 65 N 1 1 4
14 63 F 21 13 N L M1 5 41 N 2 3 1
15 87 M 19 27 Y R ICA 5 54 Y (Merci, PLASTY) 4 0 6
16 63 M 18 12 N R M1 11 52 N 1 3 4
17 71 M 13 1 Y R ICA 7.5 57 Y (iaTPA) 1 2 0
18 74 M 10 Expired N R M1 16 105 N 2 3 6
19 61 M 15 12 N R M1 14 80 N 2 2 4
20 61 M 3 1 Y L M2 4 98 Y (Penum, iaTPA) 2 2 0
21 70 M 24 18 N L M1 6 70 N 1 3 4
22 73 M 9 16 N L M2 9 80 Y (Penumbra) 4 3 6
23 26 F 3 0 Y R ICA 9 30 N 1 3 0
24 77 F 8 4 Y R M1 7 26 N 1 3 1
25 65 M 15 11 Y R M2 6.5 32 N 1 2 2
26 45 F 23 5 N L M1 8 55 N 1 3 1
27 57 M 20 20 Y R M2 6.5 80 Y (TREVO, iaTPA,Penum) 2 2 NA
28 54 M 12 0 N L M1 8.5 65 N 5 3 0
29 56 F 17 5 Y L M1 6 80 N 3 2 2
30 65 M 26 17 N L ICA 7.5 75 Y(Merci) 3 3 NA
31 71 F 5 5 N L M1 13.5 25 N 1 3 1
∗Rescue treatment: procedures used in case the recanalization failed with attempt of one thrombectomy system. These include intra-arterial thrombolysis,
angioplasty, and other thrombectomy systems than the initially attempted one.
3. Results
3.1. Baseline Characteristics. Thirty-one consecutive patients
with acute ischemic stroke treated with Solitaire FR device
as a first-choice modality of mechanical thrombectomy were
included. The mean patient age was 64.1 (range: 32–87) years
and 23 (74%) were males. The NIHSS ranged from 3 to 26
(average 14, SD ± 6.02) on arrival. Arterial occlusion sites
were as follows: M1 (51%), M2 (29%), ICA or T-occlusion
(13%), and posterior circulation (6%).
Thirteen patients (42%) were treated with IV tPA prior
to arrival; however, due to persistence of symptoms and
identification of retrievable clot associated with a large area
of territory at risk on CTA and CTP, Solitaire thrombectomy
was performed.
3.2. Recanalization Rate. Table 1 summarizes the outcome
of each patient along with the recanalization grade. Twenty-
four patients (77%) were treated with the Solitaire FR as
a sole thrombectomy device and seven patients underwent
additional mode of treatment (i.e., Merci, Penumbra, Trevo,
and/or intra-arterial TPA) to achieve maximum restoration
of flow (TIMI 2 or 3). The mean time from stroke to
recanalizationwas 8.03± 3.37 (SD) hours (range: 4–17 hours).
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Figure 2: Case 14. (a) DSA of left ICA arterial phase. AP view shows an occlusion of the left M1. (b) Guiding catheter in left MCA, the distal
tip of the microcatheter, and the microwire have crossed the occluded portion of the L M1 and moved through the thrombi into M2. This
injection shows the distal end of the thrombus. (c)This AP view shows the terminal radiopaquemarker of Solitaire FR device which indicates
the start of deployment. (d) DSA of L ICA after the stent retrieval shows that the distal L MCA branches have been completely opened.
The mean procedure time defined as time between arterial
puncture to flow restoration observed on digital subtraction
angiography (DSA) was 58.5 ± 22.9 (SD) minutes overall and
only 40.3 ± 19.7 (SD) minutes for the successful procedures
that did not require other mechanical thrombectomy rescue
treatments. We obtained an overall recanalization rate (TIMI
scores of 2 and 3) of 93.5%; treatment with the Solitaire FR
device alone achieved a 79.3% recanalization rate. Only two
patients failed to recanalize. One (patient 13) had a PCA
thrombus subsequent to left vertebral artery dissection, the
tortuous anatomy precluded passage of Solitaire FR device
as well as proper deployment of stents across the dissection.
The other (patient 15) had a high clot burden with a right
ICA T-occlusion associated with distal M1 and M2 clots;
despite 3 passes with the Solitaire FR device followed by
thrombectomy with the Merci device and intra-arterial TPA
injection, reperfusion could not be achieved at level of both
the superior and inferior M2 branches.The number of device
passes ranged from 1 to 5 (average 1.8, SD ± 1.4). There were
no device fractures or arterial dissections. The NIHSS scores
at 24 hours after intervention ranged from 0 to 26 (average
9.8, SD ± 6.9), while NIHSS at discharge ranged from 0 to 27
(average 7.2, SD ± 7.1).
3.3. Recanalization Grade and Improvements in NIHSS. At
discharge, eighteen patients (58%) had a good outcome
(NIHSS improvement of ≥5), six (19%) had a fair outcome
(NIHSS improvement of 1–4), and seven (23%) had a poor
outcome (no improvement or worsening NIHSS). Table 2
summarizes patient recovery with respect to TIMI grade. Of
note, 15 of 18 patients (83%) with good NIHSS outcome at
discharge had TIMI 3, while 7 out of 13 patients (54%) with
fair or poor outcome did not achieve complete recanalization.
When this data was analyzed with Fisher’s exact test, it was
found that TIMI 3 perfusion was a statistically significant
predictor of good outcome at discharge (𝑃 = 0.012).
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Table 2: Recanalization grade as compared with NIHSS outcome at
time of discharge.
Good Fair Poor
TIMI 3 15 2 4
TIMI 2 3 4 1
TIMI 0 or 1 0 0 2
Bold emphasizes 15 of 18 patients (83%) with good NIHSS outcome at
discharge had TIMI 3, while 7 out of 13 patients (54%) with fair or poor
outcome did not achieve complete recanalization (TIMI 2 or 1).
Table graphically shows that TIMI 3 perfusion was a statistically significant
predictor of good outcome at discharge (𝑃 = 0.012).
3.4. Clinical Outcomes and Safety. At three to six months,
69% of the patients had mRS ≤ 2 (see Table 1). Two patients
were lost to followup and were not included in the analysis.
Therewas no treatment-relatedmortality.The overall mortal-
ity rate after 3–6 months of followup was 10.3% (total of three
patients including one inpatient mortality due to malignant
cerebral edema and family withdrew care). No symptomatic
hemorrhagic complications were observed after intervention.
Seven patients had asymptomatic petechial hemorrhage in
the stroke territory on 24 hour postintervention CT head.
Luxury perfusion (contrast medium enhancement in CT
head) was observed in 13 cases (41.9%). Figure 2 illustrates
the typical Solitaire thrombectomy procedure in patient
14. Postprocedural minor groin hematoma occurred in 6
(Solitaire) versus 4 (Merci/Penumbra). Each group had three
CAT scan documented retroperitoneal hematoma that did
not require vascular surgical intervention.
3.5. Comparison with the Merci-Penumbra Group. A sum-
mary of patient characteristics stratified for both groups are
presented in Table 3. These confounding factors were similar
in both groups of patients. The radiographic recanalization
rate and area salvage results of the Solitaire group are
tabulated in Table 4 and those of the Merci/Penumbra group
in Table 5.
3.5.1. Recanalization Rate Comparison. In the Merci/Penum-
bra group, ten patients (50%) achieved a TIMI grade of
3, five patients (25%) achieved a TIMI grade of 2, and 5
failed to recanalize (3 TIMI1 and 2 TIMI0). Similarly to the
Solitaire group, when the recanalization was not attained,
rescue procedure was taken with another device or ia-TPA.
Four patients required additional rescue treatment in this
group. Average procedure time was 70.8 minutes.
There was a trend towards higher recanalization rates
(TIMI 2-3) (93.5% versus 75%, 𝑃 = 0.096) and shorter
length of procedure (58.5min versus 70.8min, 𝑃 = 0.08)
in the Solitaire group versus the Merci/Penumbra group.
However, no statistical difference was reached with respect
to recanalization grade and time of procedure.
3.5.2. Clinical Outcome Comparison. In theMerci/Penumbra
group, the average 90-day mRS was 4 (SD ± 2). Seven of
Figure 3: Top shows CT head perfusion study with mismatch in
mean transit time and blood volume. Bottom shows smaller final
completed stroke area in DWI sequence of MRI. Both used to
calculate percentage area salvage.
20 (35.0%) patients had mRS ≤ 2. Three patients had symp-
tomatic intracranial hemorrhage and the 90-day mortality
rate was 45% (9 out of 20).
The 90-day mRS was significantly better in the Solitaire
groupwith 69% versus 35% achievingmRS≤ 2 (𝑃 = 0.03) and
the hemorrhagic complication rate was significantly higher in
the Merci/Penumbra group (0% versus 15%, 𝑃 = 0.05).
3.5.3. Area Salvage Comparison. The mean percentage sal-
vage area was significantly larger in the Solitaire group (81.9%
± 17.6) versus the Merci/penumbra group (71.9% ± 19.7) (𝑃 =
0.05).
4. Discussion
4.1. Key Results and Interpretation. We assessed the safety,
efficacy, and clinical outcome of the Solitaire FR system in
our institution and compared these results with a group
of patients treated with the Merci/Penumbra system. Most
recently, two randomized clinical trials (SWIFT andTREVO2
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Table 3: Baseline demographic and clinical characteristics of the patients.
Solitaire (𝑛 = 31) Merci/Penumbra (𝑛 = 20)
Age (years; range) 64.1 (32–87) 67.5 (31–85) 𝑃 = 0.02
Sex (% male) 74% 65% 𝑃 = 0.07
NIHSS score (Mean; Range) 13.7 (3–26) 14.3 (8–22) 𝑃 = 0.17
Body-mass index (mean) 28 29 𝑃 = 0.03
ivTPA administration 42% 45% 𝑃 = 0.02
Medical history
HTN 75% 70%
DM 17% 25%
Smoking 42% 40%
Atrial Fibrillation 35% 45%
Use of antiplatelet or anticoagulation 48% 55%
Most proximal occlusion location
Internal carotid artery 13% 25%
M1 middle cerebral artery 51% 50%
M2 middle cerebral artery 29% 20%
Posterior circulation 6% 5%
Occlusion side (left) 61% 55%
Time to arterial puncture (min; range) 432min (242–962min) 351min (240–600min)
Table 4: Results of Solitaire tabulated for area of salvage, recanalization rate, intervention time and clinical results.
Patient Age Gender NIHSS onarrival
NIHSS at
24 h ivTPA
Location
of
thrombus
% Salvage
Time to
reperfusion
(hrs)
Procedure
time (min) TIMI
Symptomatic
ICH mRS
1 87 F 18 13 N R M2 61 17 42 3 N 4
2 64 M 12 7 N L M1 90.7 11 90 3 N 1
3 73 M 12 8 Y L M1 1 7 36 3 N 2
4 32 M 18 5 Y R M2 83.5 5 33 3 N 0
5 50 M 21 7 N R ICA 61.4 5 65 2 N 1
6 52 M 7 3 N Basilar NA 6 73 3 N 0
7 76 M 12 6 N R M1 95.2 10 44 3 N 2
8 77 M 13 3 Y R M1 1 6 65 2 N 0
9 62 M 9 7 N L M2 1 5 70 2 N 2
10 77 F 13 6 Y L ICA 96.9 10 80 3 N 2
11 48 M 12 1 N R M2 59 6 20 3 N 0
12 82 M 9 4 Y L M1 82.1 5 26 3 N 4
13 69 M 9 9 N L vert NA 6 65 1 N 4
14 63 F 21 16 N L M1 73.9 5 41 3 N 1
15 87 M 19 27 Y R M1 57.6 5 54 0 N 6
16 63 M 18 10 N R M1 NA 11 52 3 N 4
17 71 M 13 7 Y R ICA 95.7 7.5 57 2 N 0
18 74 M 10 10 N R M1 1 16 105 3 N 6
19 61 M 15 13 N R M1 86.6 14 80 2 N 4
20 61 M 3 2 Y L M2 90.9 4 98 2 N 0
21 70 M 24 18 N L M1 91.5 6 70 3 N 4
22 73 M 9 14 N L M2 NA 9 80 3 N 6
23 26 F 3 0 Y R ICA 88.8 9 30 3 N 0
24 77 F 8 5 Y R M1 81.1 7 26 3 N 1
25 65 M 15 11 Y R M2 90.6 6.5 32 2 N 2
26 45 F 23 17 N L M1 82.8 8 55 3 N 1
27 57 M 20 20 Y R M2 39.3 6.5 80 2 N NA
28 54 M 12 5 N L M1 97.8 8.5 65 3 N 0
29 56 F 17 18 Y L M1 28.9 6 80 2 N 2
30 65 M 26 26 N L ICA NA 7.5 75 3 N NA
31 71 F 5 7 N L M1 92.9 13.5 25 3 N 1
Average 81.9
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Table 5: Data for 20 comparison group who received Merci/Penumbra treatment.
Patient Age Sex IVtpA NIH A % Salvage Location of clot Time tointervention
Intervention
time TIMI
Symptomatic
ICH mRS at F/U
1 73 M 1 15 80.7 L M1 7 75 3 Y 2
2 85 F 0 14 73.4 L ICA 10 77 0 N 4
3 53 M 1 11 76.4 R M1 9 69 2 N 4
4 86 F 0 14 59.0 R ICA 8 88 1 N 6
5 47 M 0 14 52.4 R M2 NA 48 0 N 6
6 58 M 0 22 81.0 R M1 6 72 1 N 6
7 49 M 0 21 86.5 L M1 NA 28 3 N 3
8 86 F 1 16 83.2 L M1 4 33 3 N 2
9 63 M 1 12 97.2 R ICA 5 80 3 N 1
10 67 M 0 14 78.7 R M1 5 38 2 N 6
11 59 F 1 15 96.0 R M1 5 65 3 N 2
12 78 M 0 16 27.7 L M1 5 73 2 N 6
13 68 F 0 20 48.8 L ICA NA 111 3 N 6
14 68 M 1 22 36.8 L M1 4 113 2 Y 6
15 59 F 1 16 58.6 R M1 4 57 1 N 6
16 69 M 1 20 67.5 R ICA 7 100 3 Y 3
17 75 M 0 12 92.6 R M1 4 59 3 N 2
18 59 F 1 12 87.9 R M1 4 85 2 N 6
19 62 M 1 10 92.5 R ICA 7.5 110 3 N 1
20 67 M 1 8 61.7 L M2 5 38 3 N 2
Average 71.9 5.85 70.95
trails) have compared newer clot retrieval devices in treat-
ment of acute ischemic stroke. In the SWIFT study, patients
were significantly more likely to have flow restoration (TIMI
scale 2 or 3) and a favorable outcome with the Solitaire FR
device compared with the Merci device [4]. In the TREVO2
trial, patients treated with the Trevo device were 4.2 times
more likely to achieve revascularization, with a significantly
higher rate of favorable outcomes compared with the Merci
device [7]. In our study, we not only reproduced higher rates
of flow restoration and favorable outcomes with the Solitaire
device but also demonstrated that Solitaire patients attained
radiographically a significantly higher percentage salvage rate
than Merci/Penumbra patients.
Comparing the outcomes of the present study with
the results of five large mechanical thrombolysis trials (see
Table 6): Merci, Multi-Merci, Penumbra Pivotal, SWIFT, and
TREVO2 trials, our study obtained a higher recanalization
rate than the Merci, Multi-Merci, and Penumbra pivotal
stroke trials [3, 4, 8]. Our recanalization results were similar
to those of the SWIFT and TREVO2 trials. The clinical out-
come as represented by mRS ≤ 2 and three-month mortality
rates in our study were significantly improved compared with
all of these studies.
We believe that radiographic analysis enables more direct
comparison of treatment efficacy in restoring viable brain
tissue without introducing confounding variables such as
patients’ age, baseline heath status, and recovery process
during rehabilitation. Clinical outcome assessment by means
of mRS tends to involve these confounding factors that
modify recovery from stroke in addition to the results of
thrombectomy. Thus, in a sense, area salvage analysis is a
simpler measure for the efficacy of thrombectomy device. Of
course, in clinical medicine, our ultimate goal is to provide
better clinical outcome for patients and this necessitates
correlation between area salvage and clinical recovery from
stroke.
Other key findings include a longer procedure time
and a higher incidence of symptomatic intracranial hemor-
rhage after intervention for Merci/Penumbra group. Taken
together, these findings suggest that the Solitaire FR device
allows safer, faster, and more efficient treatment of acute
ischemic stroke patients than older devices used in our
institute.
4.2. Limitations. Our study is limited by the small num-
ber of patients treated with old generation systems: Merci
and Penumbra (only twenty patients). Because of this,
we decided to combine patients treated with Merci and
Penumbra systems together as a comparison group. Though
this demonstrated that the newest system (Solitaire FR)
is superior to the older systems, it does not effectively
convey whether the Solitaire is better than the Merci or the
Penumbra individually. This grouping does not mean that
authors believe that the Merci and the Penumbra systems
yield similar recanalization results, clinical, or radiographic
outcomes, rather it is just a grouping constructed based
on the time course of thrombolysis device used in our
institution. Another limitation is baseline characteristics of
the Solitaire group and the Merci/Penumbra groups are not
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Table 6: The outcomes of the present study compared to the results from large mechanical thrombectomy trials.
Present study Merci [9] Multi-Merci[8]
Penumbra
pivotal stroke
[3]
SWIFT trial
[10] (solitaire
arm)
TREVO2 trial
[7] (TREVO2
arm)
Sample, 𝑛 31 141 164 125 58 88
Recanalization, 𝑛 (%) 29 (93.5%)∗ 68 (48.2%) 112 (68.2%) 102 (81.6%) 48 (88.9%) 76 (86%)
symptomatic ICH, 𝑛 (%) 0 (0) 11 (7.8%) 16 (9.7%) 14 (11.2% ) 1 (1.7%) 4 (4%)
3 month mortality, 𝑛 (%) 3 (10.3%) 61 (43.2%) 56 (34.1%) 31 (32.8%) 10 (17.2%) 29 (33%)
3 month mRS ≤ 2, 𝑛 (%) 20 (69%) 39 (27.6%) 59 (35.9% ) 52 (41.6%) 32 (58.2%) 38/85 (40%)
∗This is the final recanalization rate which includes rescue treatment with other devices as well as iaTPA.With Solitaire FR device alone, the recanalization rate
was 79.5%.
matched due to the retrospective nature of the study and the
limited number of patients. Furthermore, despite that authors
do acknowledge the TREVO trial and its efficacy being
reported to be comparable if not superior to the Solitaire,
our institution does not currently have enough patients
treated with TREVO system so they were not included in
this study. Another inherent limitation of our study is its
retrospective design. The main methodological limitation to
our study relates to its small sample size causing the study
to be underpowered to detect small differences in outcome.
Our results reflect the experience of a single institution with
specific protocols formechanical thrombectomy andmay not
be entirely applicable to other centers.
5. Conclusion
We presented the first single-center study comparing the
Solitaire FR device and the Merci/Penumbra systems. We
found significantly higher recanalization rates and improved
outcomes with a statistically significant increase in the
percentage area salvaged among patients treated with the
Solitaire device. Our study adds to the growing body of
evidence supporting the safety and efficacy of mechanical
thrombectomy with the Solitaire FR system in large proximal
arterial occlusions.
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